Rosuvastatin

• Published in: PA AP no. 36; p. 38
• Main Authors: J. Honorato Pérez, I. Gil Aldea, V. Fernández Gallego
• Format: Journal Article
• Language: English
• Published: Barcelona Ediciones Mayo 01.07.2004
• Subjects: Cardiovascular disease; Clinical trials; Health risk assessment; Protease inhibitors
• ISSN: 1139-1596

Hyperlidipemia is a cardiovascular risk factor that is currently being undertreated in a high percentage of patients. Rosuvastatin is a new hydroxymethylglutaryl (HMG) CoA-reductase nhibitor that is more effective than the statins available until now and has a good safety profile. Thus, it may help a greater number of patients to achieve compensation. Clinical trials performed to date with rosuvastatin have focused on different types of hyperlipidemia and some other entities such as the metabolic syndrome, comparing it with known statins. The pharmacokinetic characteristics of rosuvastatin make it convenient to administer, a circumstance that facilitates compliance, and its low drug interaction profile avoids complications in patients that are often taking other drugs as well. The effective treatment of hyperlipidemia is associated with a reduction in the incidence of ischemic heart disease and cerebrovascular accidents, which results in a marked cost savings.